• Journal of the Korean Society of Radiology
• /
• v.12 no.6
• /
• pp.737-743
• /
• 2018

Patient exposure dose exposure test, which is one of the items of accuracy control of Computed Tomography, conducts measurements every year based on the installation and operation of special medical equipment under Article 38 of the Medical Law, And keep records. The CT-Dose phantom used for dosimetry can accurately measure doses, but has the disadvantage of high price. Therefore, through this research, the existing CT - Dose phantom was similarly manufactured with a 3D printer and compared with the existing phantom to examine the usefulness. In order to produce the same phantom as the conventional CT-Dose phantom, a 3D printer of the FFF method is used by using a PLA filament, and in order to calculate the CTDIw value, Ion chambers were inserted into the central part and the central part, and measurements were made ten times each. Measurement results The CT-Dose phantom was measured at $30.44{\pm}0.31mGy$ in the periphery, $29.55{\pm}0.34mGy$ CTDIw value was measured at $30.14{\pm}0.30mGy$ in the center, and the phantom fabricated using the 3D printer was measured at the periphery $30.59{\pm}0.18mGy$, the central part was $29.01{\pm}0.04mGy$, and the CTDIw value was measured at $30.06{\pm}0.13mGy$. Analysis using the Mann - Whiteney U-test of the SPSS statistical program showed that there was a statistically significant difference in the result values in the central part, but statistically significant differences were observed between the peripheral part and CTDIw results I did not show. In conclusion, even in the CT-Dose phantom made with a 3D printer, we showed dose measurement performance like existing CT-Dose phantom and confirmed the possibility of low-cost phantom production using 3D printer through this research did it.

• Tuberculosis and Respiratory Diseases
• /
• v.42 no.6
• /
• pp.846-854
• /
• 1995

Background: Cytokeratin 19 is a subunit of cytokeratin intermediate filament expressed in simple epithelia such as respiratory epithelial cells and their malignant counterparts. An immunoradiometric assay is available to detect a fragment of the cytokeratin, referred to as Cyfra 21-1 in the serum. This study was conducted to evaluate the clinical utility of this new marker in the diagnosis of lung cancer compared with established markers of squamous cell carcinoma antigen (SCC Ag) and carcino-embryonic antigen(CEA). In addition, we compared the diagnostic sensitivity and specificity of Cyfra 21-1 with those of SCC Ag in squamous cell carcinoma of the lung. We also measured the level of Cyfra 21-1 in the different stages of squamous cell carcinoma of the lung. Method: We measured Cyfra 21-1(ELSA-CYFRA 21-1), SCC Ag(ABBOTT SCC RIABEAD) and CEA(ELSA2-CEA) in 79 patients with primary lung cancer and in 78 persons as a comparison group including 32 patients with pulmonary tuberculosis, 23 patients with benign lung disease and 23 cases with healthy individual. Cyfra 21-1 is measured by a solid-phase immunoradiometric assay(CIS Bio International, France) based on the two-site sandwich method. SCC Ag is measured by a radioimmunoassay(Abbott Laboratories, USA). CEA is measured by a immunoradiometric assay(CIS Bio International, France). All data were expressed as the mean$\pm$standard deviation. Results: 1) The mean value of Cyfra 21-1 was $18.38{\pm}3.65\;ng/mL$ in the lung cancer and $1.l6{\pm}0.53\;ng/mL$ in the comparison group(p<0.0001). SCC Ag was $3.53{\pm}6.06\;ng/mL$ in the lung cancer and $1.19{\pm}0.5\;ng/mL$ in the comparison group(p<0.01). CEA was $35.03{\pm}13.9\;ng/mL$ in the lung cancer and $2.89{\pm}1.01\;ng/mL$ in the comparison group(p<0.0001). 2) Cyfra 21-1 level in squamous cell carcinoma($31.52{\pm}40.13\;ng/mL$) was higher than that in adenocarcinoma($2.41{\pm}1.34\;ng/mL$)(p<0.0001) and small cell carcinoma($2.15{\pm}2.05\;ng/mL$)(p=0.007). SCC Ag level in squamous cell carcinoma($5.1{\pm}7.68\;ng/mL$) was higher than that in adenocarcinoma($1.36{\pm}0.69\;ng/mL$)(p=0.009) and small cell carcinoma($1.1{\pm}0.24\;ng/mL$) (p=0.024). 3) The level of Cyfra 21-1 was not correlated with the progression of stage in squamous cell carcinoma of the lung. 4) Using the cut-off value of 3.3ng/mL, the diagnostic sensitivity of Cyfra 21-1 was 83% in squamous cell carcinoma, 22% in adenocarcinoma and 17% in small cell carcinoma. The sensitivity of SCC Ag and CEA were 39% and 20%, respectively in squamous cell carcinoma, 11% and 39% in adenocarcinoma, and 0% and 33% in small cell carcinoma. 5) Comparison of the receiver operating characteristics curves(ROC curve) for Cyfra 21-1, SCC Ag and CEA revealed that Cyfra 21-1 showed highest diagnostic sensitivity among them in the diagnosis of lung cancer. Conclusion: Cyfra 21-1 is thought to be a better tumor marker for the diagnosis of lung cancer than SCC Ag and CEA, especially in squamous cell carcinoma of the lung.